Do analysts prefer MRAI or DCGO?

DocGo has a consensus target price of $2.38, indicating a potential upside of 316.59%. Given DocGo's stronger consensus rating and higher probable upside, analysts clearly believe DocGo is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 DocGo 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has stronger valuation & earnings, MRAI or DCGO?

Marpai has higher earnings, but lower revenue than DocGo. Marpai is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Marpai $34.87M 0.41 -$28.75M -$0.87 N/A DocGo $322.20M 0.17 -$182.40M -$1.91 N/A

Is MRAI or DCGO more profitable?

DocGo has a net margin of -62.23% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat DocGo's return on equity. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% DocGo -62.23% -44.09% -29.14%

Do analysts recommend EUDA or MRAI?

EUDA Health presently has a consensus price target of $55.00, suggesting a potential upside of 237.22%. Given EUDA Health's stronger consensus rating and higher probable upside, equities analysts plainly believe EUDA Health is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score EUDA Health 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is EUDA or MRAI more profitable?

EUDA Health has a net margin of 0.00% compared to Marpai's net margin of -85.70%. Company Net Margins Return on Equity Return on Assets EUDA Health N/A N/A N/A Marpai -85.70% N/A -100.23%

Do analysts prefer CCM or MRAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Concord Medical Services 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, CCM or MRAI?

Concord Medical Services has higher revenue and earnings than Marpai. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Concord Medical Services $460.51M 0.05 -$13.27M N/A N/A Marpai $34.87M 0.41 -$28.75M -$0.87 N/A

Is CCM or MRAI more profitable?

Concord Medical Services has a net margin of 0.00% compared to Marpai's net margin of -85.70%. Company Net Margins Return on Equity Return on Assets Concord Medical Services N/A N/A N/A Marpai -85.70% N/A -100.23%

Do analysts recommend BMGL or MRAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, BMGL or MRAI?

Basel Medical Group has higher earnings, but lower revenue than Marpai. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Basel Medical Group $8.90M 1.02 -$9.50M N/A N/A Marpai $34.87M 0.41 -$28.75M -$0.87 N/A

Is BMGL or MRAI more profitable?

Basel Medical Group has a net margin of 0.00% compared to Marpai's net margin of -85.70%. Company Net Margins Return on Equity Return on Assets Basel Medical Group N/A N/A N/A Marpai -85.70% N/A -100.23%

Do analysts recommend MRAI or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MRAI or MGRX more profitable?

Marpai has a net margin of -85.70% compared to Mangoceuticals' net margin of -4,639.13%. Marpai's return on equity of 0.00% beat Mangoceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% Mangoceuticals -4,639.13% -112.00% -104.96%

Marpai (MRAI) Competitors

$0.56 +0.03 (+5.66%)

As of 03:16 PM Eastern

Compare

MRAI vs. DCGO, EUDA, CCM, BMGL, and MGRX

Should you buy Marpai stock or one of its competitors? MarketBeat compares Marpai with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Marpai include DocGo (DCGO), EUDA Health (EUDA), Concord Medical Services (CCM), Basel Medical Group (BMGL), and Mangoceuticals (MGRX). These companies are all part of the "healthcare" industry.

How does Marpai compare to DocGo?

Marpai (NASDAQ:MRAI) and DocGo (NASDAQ:DCGO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Marpai has a beta of 4.94, indicating that its stock price is 394% more volatile than the broader market. Comparatively, DocGo has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

Marpai has higher earnings, but lower revenue than DocGo. Marpai is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	0.41	-$28.75M	-$0.87	N/A
DocGo	$322.20M	0.17	-$182.40M	-$1.91	N/A

DocGo has a net margin of -62.23% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
DocGo	-62.23%	-44.09%	-29.14%

In the previous week, DocGo had 2 more articles in the media than Marpai. MarketBeat recorded 2 mentions for DocGo and 0 mentions for Marpai. DocGo's average media sentiment score of 0.63 beat Marpai's score of 0.00 indicating that DocGo is being referred to more favorably in the news media.

Company	Overall Sentiment
Marpai	Neutral
DocGo	Positive

49.8% of Marpai shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 46.1% of Marpai shares are owned by insiders. Comparatively, 3.8% of DocGo shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

DocGo has a consensus target price of $2.38, indicating a potential upside of 316.59%. Given DocGo's stronger consensus rating and higher probable upside, analysts clearly believe DocGo is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

DocGo beats Marpai on 9 of the 16 factors compared between the two stocks.

How does Marpai compare to EUDA Health?

EUDA Health (NASDAQ:EUDA) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

EUDA Health has higher earnings, but lower revenue than Marpai. EUDA Health is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EUDA Health	$6.82M	7.15	-$2.77M	-$2.40	N/A
Marpai	$34.87M	0.41	-$28.75M	-$0.87	N/A

EUDA Health has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Marpai has a beta of 4.94, indicating that its stock price is 394% more volatile than the broader market.

EUDA Health presently has a consensus price target of $55.00, suggesting a potential upside of 237.22%. Given EUDA Health's stronger consensus rating and higher probable upside, equities analysts plainly believe EUDA Health is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EUDA Health	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

4.4% of EUDA Health shares are owned by institutional investors. Comparatively, 49.8% of Marpai shares are owned by institutional investors. 46.1% of Marpai shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

EUDA Health has a net margin of 0.00% compared to Marpai's net margin of -85.70%.

Company	Net Margins	Return on Equity	Return on Assets
EUDA Health	N/A	N/A	N/A
Marpai	-85.70%	N/A	-100.23%

In the previous week, EUDA Health had 5 more articles in the media than Marpai. MarketBeat recorded 5 mentions for EUDA Health and 0 mentions for Marpai. EUDA Health's average media sentiment score of 1.13 beat Marpai's score of 0.00 indicating that EUDA Health is being referred to more favorably in the media.

Company	Overall Sentiment
EUDA Health	Positive
Marpai	Neutral

Summary

EUDA Health beats Marpai on 9 of the 15 factors compared between the two stocks.

How does Marpai compare to Concord Medical Services?

Concord Medical Services (NYSE:CCM) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Concord Medical Services has a beta of -0.99, meaning that its stock price is 199% less volatile than the broader market. Comparatively, Marpai has a beta of 4.94, meaning that its stock price is 394% more volatile than the broader market.

Concord Medical Services has a net margin of 0.00% compared to Marpai's net margin of -85.70%.

Company	Net Margins	Return on Equity	Return on Assets
Concord Medical Services	N/A	N/A	N/A
Marpai	-85.70%	N/A	-100.23%

In the previous week, Concord Medical Services' average media sentiment score of 0.67 beat Marpai's score of 0.00 indicating that Concord Medical Services is being referred to more favorably in the media.

Company	Overall Sentiment
Concord Medical Services	Positive
Marpai	Neutral

49.8% of Marpai shares are held by institutional investors. 46.5% of Concord Medical Services shares are held by company insiders. Comparatively, 46.1% of Marpai shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Concord Medical Services has higher revenue and earnings than Marpai.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Concord Medical Services	$460.51M	0.05	-$13.27M	N/A	N/A
Marpai	$34.87M	0.41	-$28.75M	-$0.87	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Concord Medical Services	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Concord Medical Services beats Marpai on 7 of the 10 factors compared between the two stocks.

How does Marpai compare to Basel Medical Group?

Basel Medical Group (NASDAQ:BMGL) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Basel Medical Group has higher earnings, but lower revenue than Marpai.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$8.90M	1.02	-$9.50M	N/A	N/A
Marpai	$34.87M	0.41	-$28.75M	-$0.87	N/A

In the previous week, Basel Medical Group had 1 more articles in the media than Marpai. MarketBeat recorded 1 mentions for Basel Medical Group and 0 mentions for Marpai. Basel Medical Group's average media sentiment score of 1.53 beat Marpai's score of 0.00 indicating that Basel Medical Group is being referred to more favorably in the media.

Company	Overall Sentiment
Basel Medical Group	Very Positive
Marpai	Neutral

Basel Medical Group has a net margin of 0.00% compared to Marpai's net margin of -85.70%.

Company	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
Marpai	-85.70%	N/A	-100.23%

Basel Medical Group has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, Marpai has a beta of 4.94, indicating that its share price is 394% more volatile than the broader market.

49.8% of Marpai shares are owned by institutional investors. 46.1% of Marpai shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Basel Medical Group beats Marpai on 7 of the 11 factors compared between the two stocks.

How does Marpai compare to Mangoceuticals?

Marpai (NASDAQ:MRAI) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

49.8% of Marpai shares are held by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are held by institutional investors. 46.1% of Marpai shares are held by insiders. Comparatively, 16.0% of Mangoceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Marpai has a beta of 4.94, meaning that its stock price is 394% more volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.27, meaning that its stock price is 127% more volatile than the broader market.

Mangoceuticals has lower revenue, but higher earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	0.41	-$28.75M	-$0.87	N/A
Mangoceuticals	$460K	14.53	-$20.64M	-$1.49	N/A

In the previous week, Mangoceuticals had 2 more articles in the media than Marpai. MarketBeat recorded 2 mentions for Mangoceuticals and 0 mentions for Marpai. Mangoceuticals' average media sentiment score of 0.63 beat Marpai's score of 0.00 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Marpai	Neutral
Mangoceuticals	Positive

Marpai has a net margin of -85.70% compared to Mangoceuticals' net margin of -4,639.13%. Marpai's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
Mangoceuticals	-4,639.13%	-112.00%	-104.96%

Summary

Marpai beats Mangoceuticals on 8 of the 14 factors compared between the two stocks.

Get Marpai News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRAI vs. The Competition

Export

Metric	Marpai	health & allied services, not elsewhere classified Industry	Business Sector	NASDAQ Exchange
Market Cap	$14.19M	$81.71M	$6.66B	$12.43B
Dividend Yield	N/A	N/A	3.05%	5.33%
P/E Ratio	-0.21	0.74	29.53	24.35
Price / Sales	0.41	0.25	415.96	115.59
Price / Cash	N/A	4.19	24.38	55.53
Price / Book	-0.33	0.15	6.00	6.72
Net Income	-$28.75M	$25.15M	$205.99M	$337.03M
7 Day Performance	-26.76%	-12.25%	2.28%	0.09%
1 Month Performance	N/A	N/A	4.67%	-1.78%
1 Year Performance	-58.52%	-22.84%	39.17%	33.98%

Marpai Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRAI Marpai	N/A	$0.56 +5.7%	N/A	-61.9%	$14.19M	$34.87M	N/A	150
DCGO DocGo	3.3709 of 5 stars	$0.63 +0.4%	$2.38 +275.4%	-61.2%	$62.21M	$322.20M	N/A	3,568
EUDA EUDA Health	2.9353 of 5 stars	$18.08 +0.4%	$55.00 +204.2%	-74.8%	$45.28M	$6.82M	N/A	2	Positive News Gap Up
CCM Concord Medical Services	0.5645 of 5 stars	$4.86 -0.5%	N/A	-37.6%	$21.23M	$65.85M	N/A	970
BMGL Basel Medical Group	0.9574 of 5 stars	$0.59 +1.7%	N/A	-87.1%	$10.89M	$8.90M	N/A	36	News Coverage Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRAI) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Marpai (MRAI) Competitors

MRAI vs. DCGO, EUDA, CCM, BMGL, and MGRX

How does Marpai compare to DocGo?

Summary

How does Marpai compare to EUDA Health?

Summary

How does Marpai compare to Concord Medical Services?

Summary

How does Marpai compare to Basel Medical Group?

Summary

How does Marpai compare to Mangoceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRAI vs. The Competition

Marpai Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Marpai (MRAI) Competitors

MRAI vs. DCGO, EUDA, CCM, BMGL, and MGRX

How does Marpai compare to DocGo?

Which has more volatility and risk, MRAI or DCGO?

Which has stronger valuation & earnings, MRAI or DCGO?

Is MRAI or DCGO more profitable?

Does the media refer more to MRAI or DCGO?

Do insiders & institutionals believe in MRAI or DCGO?

Do analysts prefer MRAI or DCGO?

Summary

How does Marpai compare to EUDA Health?

Which has higher valuation and earnings, EUDA or MRAI?

Which has more volatility and risk, EUDA or MRAI?

Do analysts recommend EUDA or MRAI?

Do insiders and institutionals hold more shares of EUDA or MRAI?

Is EUDA or MRAI more profitable?

Does the media prefer EUDA or MRAI?

Summary

How does Marpai compare to Concord Medical Services?

Which has more risk and volatility, CCM or MRAI?

Is CCM or MRAI more profitable?

Does the media favor CCM or MRAI?

Do insiders & institutionals hold more shares of CCM or MRAI?

Which has stronger valuation and earnings, CCM or MRAI?

Do analysts prefer CCM or MRAI?

Summary

How does Marpai compare to Basel Medical Group?

Do analysts recommend BMGL or MRAI?

Which has stronger valuation and earnings, BMGL or MRAI?

Does the media prefer BMGL or MRAI?

Is BMGL or MRAI more profitable?

Which has more volatility & risk, BMGL or MRAI?

Do institutionals and insiders believe in BMGL or MRAI?

Summary

How does Marpai compare to Mangoceuticals?

Do analysts recommend MRAI or MGRX?

Do insiders and institutionals have more ownership in MRAI or MGRX?

Which has more risk and volatility, MRAI or MGRX?

Which has preferable valuation & earnings, MRAI or MGRX?

Does the media refer more to MRAI or MGRX?

Is MRAI or MGRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRAI vs. The Competition

Marpai Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools